8月5日，益丰药房大宗交易成交2352.65万股，成交额5.38亿元，占当日总成交额的85.48%，成交价 22.88元，较市场收盘价24.45元折价6.42%。 | 交易日期 | 证券同核 | 证券代品 | | | 痰交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 群用易不错 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-05 | 草本配送 | 603939 | 22.88 | 204.55 | 8.94 | 机构专用 | 中信证券股份有限 公司减附分公司 | 零 | | 2025-08-05 | 草丰厨房 | 603839 | 22.88 | 203.63 | 8.9 | 机构专用 | 中信证券股份有限 公司湖南分公司 | Ka | | 2025-08-05 | 草本配送 | 603939 | 22.88 | 202.95 | 8.87 | 机构专用 | 中信证券股份有限 公司湖南分公司 | 整 | | 2025-08-05 | 群主经论 | 603939 | 22.88 | 202. ...

Core Viewpoint - The company has announced an extension of the completion date for its fundraising investment project, the "Yifeng Digital Platform Upgrade Project," from July 31, 2025, to December 31, 2025, without changing the project implementation subject, method, total investment amount, or purpose [2][5][6]. Fundraising Basic Information - The company issued 17,974,320 convertible bonds at a face value of RMB 100 each, raising a total of RMB 1,797.432 million. After deducting underwriting and sponsorship fees, the net amount raised was RMB 1,780.932 million [3][4]. Fundraising Usage Status - As of June 30, 2025, the company has invested RMB 73.621 million in the "Yifeng Digital Platform Upgrade Project," achieving an investment progress of 91.29% against a planned total investment of RMB 80.642 million [4]. Reasons for Project Delay - The delay in the "Digital Project" is due to the complexity of integrating multiple systems (product, logistics, finance, and human resources), which has led to challenges in platform integration and promotion. Additionally, some expenses related to personnel salaries and social insurance cannot be paid directly from the fundraising account, necessitating the use of self-owned funds initially [5][6]. Impact of Project Delay - The project delay is a prudent decision based on the actual implementation situation and will not adversely affect the company's normal operations or harm the interests of shareholders, particularly minority shareholders. The decision aligns with the company's long-term development plan [6][8]. Review Procedures and Opinions - The board of directors and the supervisory board approved the extension of the project completion date during meetings held on July 30, 2025. The supervisory board expressed agreement with the decision, confirming compliance with relevant laws and regulations [7][8][9].

证券代码：603939 证券简称：益丰药房 公告编号：2025-070 债券代码：113682 债券简称：益丰转债 益丰大药房连锁股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (二) 股东会召集人：董事会 召开的日期时间：2025 年 8 月 25 日 14 点 30 分 召开地点：湖南省长沙市金洲大道 68 号益丰医药物流园三楼会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 8 月 25 日 至2025 年 8 月 25 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务 ...

第二条 本制度适用于公司董事（含独立董事、职工代表董事）、高级管理 人员因任期届满、辞职、被解除职务或其他原因离职的情形。 第一章 总则 第一条 为规范益丰大药房连锁股份有限公司（以下简称"公司"）董事、高 级管理人员离职管理，保障公司治理稳定性及股东合法权益，根据《中华人民 共和国公司法》（以下简称《公司法》）、《上市公司章程指引》《上市公司 董事和高级管理人员所持本公司股份及其变动管理规则》等法律法规、规范性 文件和《公司章程》的规定，制定本制度。 益丰大药房连锁股份有限公司 董事、高级管理人员离职管理制度 第三条 公司董事、高级管理人员离职管理应遵循以下原则： （一）合法合规原则：严格遵守国家法律法规、监管规定及《公司章程》 的要求； 第二章 离职情形与程序 第四条 公司董事、高级管理人员离职包含任期届满未连任、主动辞职、被解除 职务以及其他导致董事实际离职等情形。 第五条 公司董事、高级管理人员可以在任期届满以前辞任。公司董事、高 级管理人员辞任应当提交书面辞职报告。高级管理人员辞任的，自董事会收到 辞职报告时生效。 第六条 公司应在收到辞职报告后2个交易日内披露董事、高级管理人员离 任公告，应当在公 ...

Core Viewpoint - The company plans to use its own funds to pay part of the expenses for the "Digital Platform Upgrade Project" and subsequently replace these with raised funds, amounting to no more than 7.05 million yuan [1][4]. Fundraising Basic Situation - The company issued 17,974,320 convertible bonds at a face value of 100 yuan each, raising a total of 1.797 billion yuan, with net proceeds after deducting issuance costs amounting to 1.327 billion yuan [1][2]. Investment Project Basic Situation - As of June 30, 2025, the total investment for the projects is 2.534 billion yuan, with 1.797 billion yuan planned to be funded by the raised funds, and 443.06 million yuan already utilized [2][3]. Reasons for Using Own Funds - The company needs to use its own funds for salary and social insurance payments during the project implementation, as these payments must be processed through the company's basic deposit account [3][4]. Impact on the Company - The use of self-funds followed by replacement with raised funds is expected to enhance the efficiency of fund utilization and overall operational management, ensuring the smooth progress of the investment project [4][5]. Review Procedures and Opinions - The board and supervisory committee approved the proposal to use self-funds for the project, confirming that this does not harm the interests of the company or its shareholders and complies with relevant regulations [5][6].

Core Viewpoint - The company has announced an extension of the completion date for its fundraising investment project, the "Digital Platform Upgrade Project," from July 31, 2025, to December 31, 2025, without changing the project implementation subject, method, total investment, or use of funds [1][4]. Fundraising Basic Information - The company issued 17,974,320 convertible bonds at a face value of RMB 100 each, raising a total of RMB 1.797 billion, with net proceeds after deducting issuance costs amounting to RMB 1.793 billion [1][2]. Fundraising Usage Status - As of June 30, 2025, the total investment for the "Digital Platform Upgrade Project" is RMB 80.642 million, with RMB 73.621 million already invested, representing a progress rate of 91.29% [2][3]. Reasons for Project Delay - The delay in the "Digital Project" is attributed to the complexity of integrating multiple systems (product, logistics, finance, and human resources), which has led to challenges in platform integration and promotion [3][4]. Impact of Project Delay - The project delay is a cautious decision based on actual implementation conditions and will not adversely affect the company's normal operations or harm the interests of shareholders, particularly minority shareholders [4][5]. Review Procedures and Opinions - The board of directors and the supervisory board approved the extension of the project completion date during meetings held on July 30, 2025, confirming that the decision complies with relevant laws and regulations [4][5].

益丰大药房连锁股份有限公司 投资者关系管理制度 （经第五届董事会第十九次会议审议通过） 第一章 总则 第一条 为促进和完善益丰大药房连锁股份有限公司（以下简称"公司"） 治理结构，规范公司投资者关系管理工作，切实保护投资者特别是社会公众投资 者的合法权益，根据《中华人民共和国公司法》、《中华人民共和国证券法》《上 海证券交易所股票上市规则》《上市公司投资者关系管理工作指引》及其他相关 法律、法规和规定，并结合公司的实际情况，特制定本制度。 第二条 投资者关系管理是指公司通过各种方式的投资者关系活动，加强与 投资者和潜在投资者（以下统称"投资者"）之间的沟通和交流，增进投资者对 公司的了解，以实现公司、股东及其他相关利益者合法权益最大化和保护投资者 合法权益的一项战略性管理行为。 第二章 投资者关系管理的基本原则、目的及工作对象 第三条 投资者关系管理的基本原则 （一）合规性原则。公司投资者关系管理应当在依法履行信息披露义务的基 础上开展，符合法律、法规、规章及规范性文件、行业规范和自律规则、公司内 部规章制度，以及行业普遍遵守的道德规范和行为准则； （二）平等性原则。公司开展投资者关系管理活动，应当平等对待所 ...

Core Points - The document outlines the external investment management system of Yifeng Pharmacy Chain Co., Ltd, aiming to strengthen internal controls, standardize investment behavior, and mitigate risks associated with external investments [1][2] - The system is designed to ensure scientific decision-making, standardized operations, and effective investment outcomes [2][3] Group 1: General Principles - External investments are defined as actions taken by the company to allocate resources such as cash, physical assets, and intangible assets to other organizations or individuals for long-term returns [2] - The principles governing external investments include compliance with national laws and regulations, alignment with the company's long-term development strategy, and safeguarding the fundamental interests of the company and its shareholders [4][5] Group 2: Approval Authority - The decision-making bodies for external investments include the shareholders' meeting, board of directors, and the general manager, each with specific approval authority based on the transaction amount relative to the company's audited net assets [6][7] - Transactions below 3% of the latest audited net assets can be decided by the CEO, while those between 3% and 10% require the chairman's approval, and transactions exceeding 10% or 10 million yuan must be approved by the board [8][9] Group 3: Project Evaluation and Management - The company is responsible for conducting feasibility studies and evaluations for external investment projects, considering factors such as business scale, industry, expected returns, and compliance with regulations [20][21] - The financial department manages the financial aspects of external investments, including funding, registration, and compliance with strict borrowing and payment procedures [22][23] Group 4: Execution and Control - After approval, the investment plan must specify funding amounts, methods, and responsible personnel, with any changes requiring further approval [28][29] - The company must ensure that any assets used for investment are evaluated by qualified institutions, and the results must be approved by the relevant decision-making bodies [30] Group 5: Monitoring and Supervision - The company is tasked with tracking the performance of external investments and reporting to the board at least annually for three years post-investment [39] - The internal audit department is responsible for overseeing investment activities, ensuring compliance with approval processes, and verifying the accuracy of financial records related to investments [40][41]

Core Points - Yifeng Pharmacy Chain Co., Ltd. is established as a joint-stock company in accordance with the Company Law and Securities Law of the People's Republic of China [1][2] - The company was approved for public offering of 40 million shares and listed on the Shanghai Stock Exchange on February 17, 2015 [1][2] - The registered capital of the company is RMB 1,212,432,297 [2][4] Chapter 1: General Provisions - The purpose of the articles is to protect the legal rights of the company, shareholders, employees, and creditors [1] - The company is registered in Changde City, Hunan Province, with a business license number of 430700000011314 [1][2] - The chairman serves as the legal representative of the company, and the company must appoint a new legal representative within 30 days if the current one resigns [2][3] Chapter 2: Business Objectives and Scope - The company's business objective is to provide valuable goods and services for human health [4] - The business scope includes food sales, drug retail, medical services, and various other health-related services [4][5] Chapter 3: Shares - The company's shares are issued in the form of stocks, with a total of 1,212,432,297 shares, all of which are ordinary shares with a par value of RMB 1 [7][18] - The issuance of shares follows principles of openness, fairness, and justice, ensuring equal rights for all shareholders of the same class [7][8] - The company can increase capital through various methods, including issuing shares to unspecified objects or existing shareholders [20][21] Chapter 4: Shareholders and Shareholder Meetings - Shareholders have rights to dividends, attend meetings, supervise the company, and access company documents [12][13] - The company must hold an annual general meeting within six months after the end of the previous fiscal year [46] - Shareholders holding more than 10% of shares can request a temporary shareholder meeting [52][53] Chapter 5: Board of Directors - The board of directors is responsible for the company's operations and must report to the shareholders [72] - Directors must act in the best interest of the company and its shareholders, adhering to legal and regulatory requirements [40][41] - The board must ensure that the company maintains its independence and integrity in operations [41][42]

证券日报网讯 7月30日晚间，益丰药房发布公告称，公司于2025年7月30日召开第五届董事会第十九次 会议和第五届监事会第十三次会议审议通过了《关于使用自有资金支付募投项目部分款项并以募集资金 等额置换的议案》。公司拟在"益丰数字化平台升级项目"实施期间以不超过705.00万元募集资金等额置 换自有资金先行支付的相关支出，该部分等额置换资金视同募投项目使用资金。本次募集资金等额置换 的事项无需提交股东会审议。 （编辑 任世碧） ...